Spyre Therapeutics Inc. (SYRE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Spyre Therapeutics Inc. (SYRE) has a cash flow conversion efficiency ratio of -0.063x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-69.88 Million) by net assets ($1.10 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SYRE market cap for the company's overall valuation and market capitalisation.
Spyre Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Spyre Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Spyre Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Spyre Therapeutics Inc. ranked by their cash flow conversion efficiency. See cash flow to debt ratio of Spyre Therapeutics Inc. to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Suzhou Maxwell Technologies Co Ltd Class A
SHE:300751
|
0.005x |
|
BOK Financial Corporation
NASDAQ:BOKF
|
0.015x |
|
Hindustan Petroleum Corporation Limited
NSE:HINDPETRO
|
0.291x |
|
Viavi Solutions Inc
NASDAQ:VIAV
|
-0.031x |
|
Sichuan Em Technology Co Ltd
SHG:601208
|
-0.017x |
|
NEMETSCHEK UNSP.ADR/02
F:NEM0
|
N/A |
|
Wallenius Wilhelmsen Logistics ASA
OL:WAWI
|
0.135x |
|
Stantec Inc
TO:STN
|
0.035x |
Annual Cash Flow Conversion Efficiency for Spyre Therapeutics Inc. (2014–2025)
The table below shows the annual cash flow conversion efficiency of Spyre Therapeutics Inc. from 2014 to 2025. View Spyre Therapeutics Inc. stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $715.24 Million | $-169.25 Million | -0.237x | +22.16% |
| 2024-12-31 | $517.80 Million | $-157.41 Million | -0.304x | +44.01% |
| 2023-12-31 | $184.02 Million | $-99.91 Million | -0.543x | +65.92% |
| 2022-12-31 | $50.30 Million | $-80.14 Million | -1.593x | -148.96% |
| 2021-12-31 | $83.94 Million | $-53.72 Million | -0.640x | -18.09% |
| 2020-12-31 | $139.83 Million | $-75.78 Million | -0.542x | +50.44% |
| 2019-12-31 | $60.08 Million | $-65.69 Million | -1.093x | -129.01% |
| 2018-12-31 | $67.43 Million | $-32.19 Million | -0.477x | +2.36% |
| 2017-12-31 | $50.34 Million | $-24.61 Million | -0.489x | -63.43% |
| 2016-12-31 | $62.97 Million | $-18.84 Million | -0.299x | +1.63% |
| 2015-12-31 | $36.10 Million | $-10.98 Million | -0.304x | +92.24% |
| 2014-12-31 | $1.87 Million | $-7.33 Million | -3.918x | -- |
About Spyre Therapeutics Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative … Read more